Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36 ... and the technology-centric Nasdaq decreased by 0.23%. Shares of the company witnessed a loss ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

Citing positive developments in its development programs, analysts from a couple of investment banks think CRISPR Therapeutics (NASDAQ: CRSP) could more than double your money in the year ahead.

CRISPR Therapeutics (NASDAQ: CRSP) stock has been in the doldrums over the past year, down more than 30%. The stock had soared quite a bit prior to the launch of the company's first product ...

High-rolling investors have positioned themselves bullish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note. \This activity came to our attention today ...

CASGEVY, a groundbreaking gene-edited therapy developed in collaboration with CRISPR Therapeutics (NASDAQ: CRSP), has received approval for SCD and TDT, marking a significant advancement in gene ...

CRISPR Therapeutics (NASDAQ: CRSP) reached a major milestone in recent years. The company won its first regulatory approval for a product based on its gene-editing technology. In fact, this ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...